Industry frets as Trump mulls drug price pegs

The Trump administration is reportedly revisiting a contentious drug pricing strategy that would tie US medicine prices to those paid in other developed nations, according to a Reuters report citing multiple industry sources.

The proposal, which is said to be under consideration by the Centers for Medicare and Medicaid Services, has not been publicly confirmed but is understood to be gaining traction within government health agencies.

Industry insiders believe the measure poses a serious risk to the pharmaceutical sector, potentially exceeding concerns over looming tariffs on drug imports.